- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00074997
An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection
June 17, 2016 updated by: Janssen-Cilag Pty Ltd
A Randomized Phase II, Double-Blind, Controlled Trial to Evaluate the Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With Placebo or an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection
The purpose of this study is to determine the safety and efficacy of administration of a cell-delivered ribozyme gene transfer product to participants with chronic (lasting a long time) Human Immunodeficiency Virus Type 1 (HIV-1) infection (a life-threatening infection which you can get from an infected person's blood or from having sex with an infected person).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized (study drug assigned by chance), double-blind (neither the participant nor the physician know the study medication drug name), placebo (an inactive substance that is compared with a drug to test if the drug has a real effect in a clinical trial) controlled study to investigate safety and efficacy of administration of autologous cluster of differentiation 34 (CD34+) cells transduced with placebo or an anti-HIV-ribozyme (OZ1) in participants with HIV-1 infection.
The total study duration will be 100 weeks and will include following visits: screening, pre-infusion Days 1-7, Day 8, Week 1, 4, 8, 12, 16, 20, 24, 25, 26, 27, 28, 30, 32, 34, 36, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 and 100.
Before the administration of CD34+ final cell product, a number of procedures will be performed, including the injection of granulocyte colony-stimulating factor (G-CSF) to mobilize the CD34+ cells, apheresis and the transduction of the CD34+ cells with either OZ1 or placebo.
Participants will be divided into two groups: one group will receive OZ1-containing CD34+ cells, the other group will receive CD34+ cells alone and will receive a single intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) of CD34+ cells transduced with either placebo or OZ1 gene transfer product.
The final cell product contains approximately 2-20 x 10^7 cells/kilogram autologous CD34+ cell suspension transduced with either placebo or OZ1 gene transfer product.
Primary efficacy will be assessed primarily by the amount of HIV ribonucleic acid (RNA) (viral load).
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Darlinghurst, Australia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- An Human Immunodeficiency Virus 1 (HIV-1) infection for at least 6 months documented by positive HIV serology including confirmation by Western Blot
- Receiving either the first or second regimen of antiretroviral therapy (ART) defined as 3 or more antiretroviral drugs in combination
- A Viral load less than 400 copies per milliliter (copies/ml), as measured by Roche Amplicor HIV-1 Monitor assay, on 2 consecutive occasions, at least 7 days apart and within 45 days prior to granulocyte colony-stimulating factor (G-CSF) administration and the second measurement has to be within 14 days prior to G-CSF
- Cluster of Differentiation 4 (CD4+) cell count must be greater that 300 cells per cubic millimeter (cells/mm^3)
- Women and men (or their partners) had to agree to use a medically accepted form of contraception and safe sexual practices
Exclusion Criteria:
- Any previous or current Acquired Immunodeficiency Syndrome (AIDS) defining illness by the Center for Disease Control (CDC) case definition, including AIDS-related dementia (mental decline), with the exception of Kaposi's sarcoma (purple or brown cancerous pimples on the skin, often associated with AIDS)
- Clinically significant clinical laboratory results
- Participants with veins unsuitable for study related procedures
- Current ART that included antiretroviral agents which exhibited antagonism when used together (example, zidovudine and stavudine ), or current or previous ART that included hydroxyurea
- Current pregnancy or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
|
Single intravenous infusion of OZ1.
Autologous CD34+ cells.
|
Placebo Comparator: 002
Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
|
Autologous CD34+ cells.
Single intravenous infusion of placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in viral load between the placebo and OZ1 groups.
Time Frame: Week 47
|
Week 47
|
Difference in viral load between the placebo and OZ1 groups.
Time Frame: Week 48
|
Week 48
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CD4+ cell count
Time Frame: Weeks 41 - 48
|
Weeks 41 - 48
|
HIV proviral DNA
Time Frame: Weeks 41 - 48
|
Weeks 41 - 48
|
Thymic function
Time Frame: Weeks 41 - 48
|
Weeks 41 - 48
|
Time to resumption of antiretroviral therapy
Time Frame: Weeks 41 - 48
|
Weeks 41 - 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Primary Completion (Actual)
January 1, 2008
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
December 28, 2003
First Submitted That Met QC Criteria
December 30, 2003
First Posted (Estimate)
December 31, 2003
Study Record Updates
Last Update Posted (Estimate)
June 20, 2016
Last Update Submitted That Met QC Criteria
June 17, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR010783
- OZ1-HV1-201
- OTH/OZ1-INT-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsCompletedHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaCompleted
-
Gilead SciencesCompleted
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry of Health...Completed
-
Tibotec Pharmaceuticals, IrelandCompletedHIV-1United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
-
Tibotec Pharmaceuticals, IrelandCompletedHIV-1United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma B.V.; ... and other collaboratorsCompleted
-
Janssen Pharmaceutica N.V., BelgiumCompleted
Clinical Trials on OZ1
-
Janssen-Cilag Pty LtdCompleted